Latest Tax Incentives News

Neurotech International has received a $4.73 million R&D tax incentive refund, reinforcing its clinical development efforts in paediatric neurological disorders. The funds will support ongoing trials and working capital needs.

Proteomics International Laboratories has secured a $2.2 million Australian Government R&D tax rebate, reinforcing its financial position as it advances a promising pipeline of diagnostic tests based on its proprietary Promarker® technology.

RocketBoots Limited has renewed its pivotal contract with a major Australian retailer, extending an eight-year partnership and securing upfront cash payments. The company also anticipates additional inflows from banking sector pilots and R&D tax incentives, underpinning its growth trajectory.

Elixir Energy’s upcoming Lorelle-3 appraisal well in Queensland’s Taroom Trough has qualified for a substantial federal R&D tax incentive, covering nearly half of its drilling and testing costs. This financial boost underpins the company’s ambitious plans to validate a major gas play in 2026.

Immutep Limited has received a significant A$4.6 million cash payment from the French government’s R&D tax incentive scheme, supporting its ongoing immunotherapy clinical programs.

Greenvale Energy’s maiden drilling at the Oasis Uranium Project delivers multiple high-grade uranium intercepts, while the company expands its tenure in the Northern Territory’s prolific Pine Creek region.

InteliCare Holdings reported a $834,000 operating cash outflow for Q3 2025 but bolstered its balance sheet with a $1.8 million capital raise, positioning itself to sustain operations over the coming quarters.

Strategic Elements Ltd has marked a key milestone by successfully fabricating Energy Ink™ prototype cells in a commercial setting, while expanding its artificial intelligence ventures and maintaining a robust financial position.

Cynata Therapeutics is on track to deliver key clinical trial results in mid-2026 while maintaining a solid cash runway supported by an imminent R&D tax rebate and equity facility.

Acrux Limited reports robust revenue growth in Q1 FY26, driven by strong profit share income from recently launched topical pharmaceuticals and a significant R&D tax rebate repayment.

Nexsen Limited has successfully completed an $8 million IPO and ASX listing, while advancing its kidney diagnostic tests and initiating clinical trials for its GBS Rapid Sensor targeting expedited FDA approval.

Cadoux Limited has made significant progress in its High Purity Alumina (HPA) front-end engineering design and advanced the Minhub rare earths feasibility study, positioning itself strongly in the evolving critical minerals market.